Analysis, trends and data stories from the Clival team, newest first.
Featured
Bottom line is, 2026 will is going to be one of the most important years for healthcare sector. So let’s dive in, and get a better look at what next year have up it’s sleeves.
Read article
Explore how Phase I drug formulations transition from lab research to human testing, shaping the foundation for safe and effective clinical development.
Read article
The global herbal medicine market is booming, and at its heart lies Traditional Chinese Medicine (TCM).
Read article
Antimicrobial resistance (AMR) is getting scary. Experts say that by 2050, it could cause 10 million deaths every year if we don’t act.
Read article
Generics and biosimilars both make drugs cheaper, but they behave very differently after a patent dies.
Read article
For pharma leaders, investors, and business development teams, these five years represent both risk and opportunity on a historic scale.
Read article
Here’s what that means: traditional anticoagulants—like warfarin and LMWHs—still form the backbone of hospital and community care
Read article
Companies have realized the era of innovation and advance drug developments is around the corner. One of the key areas that is witnessing a surge is monoclonal antibodies.
Read article
Artificial intelligence (AI) has become a transformative force in the increasingly digitized healthcare environment.
Read article
2025 is not just another year, a wave of innovation is crashing through biotech and bioinformatics, reshaping every stage of clinical development.
Read articlePage 4 of 9 · 86 articles